Clinical trials
Epithelial Ovarian Cancer clinical trials
Below are recruiting epithelial ovarian cancer clinical trials, each written for real people, not researchers. We’re tracking 235 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07460180RecruitingPhase 1/Phase 2
PARP inhibitor with chemo and HIPEC for ovarian cancer
This trial tests if adding a drug called a PARP inhibitor (which helps block cancer cells from repairing themselves) to standard chemotherapy and heated chemotherapy during surgery (HIPEC) can work better together for ovarian cancer that has already been treated with initial chemo. It is for people with a specific type of advanced ovarian cancer who are planning surgery after chemo.
AmsterdamAges 18–100 - NCT07432633RecruitingPhase 1/Phase 2
Imaging scan to detect cancer-linked protein in several tumor types
This trial tests a new PET scan tracer that targets a protein found on certain cancer cells. It may help doctors better see and understand tumors in people with colorectal, gastric, pancreatic, lobular breast, or ovarian cancer.
Dallas, TexasAges 18–80 - NCT05200260RecruitingPhase 2
Surgery plus maintenance medicines for advanced ovarian cancer
This trial checks whether having surgery to remove as much tumor as possible, followed by ongoing targeted treatment, helps people with advanced ovarian (and related) cancers live longer and/or control cancer better. It specifically uses tumor-testing results to match patients and then continues treatment after surgery.
FoshanAges 18 years+ - NCT05737303RecruitingPhase 3
First-line chemotherapy comparison for advanced ovarian cancer
This Phase 3 trial compares two chemotherapy drug approaches (nab-paclitaxel vs another taxane drug) as the first treatment for advanced ovarian, fallopian tube, or peritoneal cancer. It aims to find which option works better and is tolerated better in people with stage III–IV disease.
Guangzhou, GuangdongAges 18–75 - NCT06085404Recruiting
Growing lab-mini-tumors for ovarian cancer treatment choices
This trial uses a small piece of your cancer tissue (taken during surgery) to grow 'mini-tumors' in the lab. These help doctors find which treatments might work best for you. It is for people with advanced serous ovarian cancer.
RomaAges 18–80 - NCT07318558RecruitingPhase 3
Study of Sac-TMT for advanced ovarian cancer without HRD
This trial is testing a new drug called Sac-TMT for people with advanced ovarian cancer that has not responded well to initial platinum-based chemotherapy and does not have a specific gene change called HRD. It aims to see if this drug can work better than standard treatment.
Birmingham, AlabamaAges 18 years+ - NCT07322094RecruitingPhase 1/Phase 2
Study of TORL-1-23 plus chemo before surgery for advanced ovarian cancer
This trial tests a new drug, TORL-1-23, given with chemotherapy before surgery for women with advanced ovarian cancer. It aims to see if this combination is safe and effective in shrinking tumors before they are removed.
Fullerton, CaliforniaAges 18–75 - NCT06324175Recruiting
Spatial radiogenomics study for ovarian cancer
This study looks at how medical images relate to genetic patterns in high-grade serous ovarian cancer. It may help find better ways to diagnose and treat this specific type of ovarian cancer.
RomaAges 18 years+ - NCT07303894RecruitingPhase 2
Isoquercetin for ovarian cancer patients
This trial tests if a plant-based supplement called isoquercetin can help people with ovarian cancer when given alongside their first chemotherapy. It aims to see if it improves treatment results.
Boston, MassachusettsAges 18 years+ - NCT06791460RecruitingPhase 2/Phase 3
A study of two drug combinations for ovarian cancer that came back
This trial tests a common chemotherapy (Pegylated Liposomal Doxorubicin) plus an immunotherapy (Adebrelimab), with or without a bladder medication (Mirabegron), in people whose ovarian cancer has returned after initial treatment. The goal is to see if adding Mirabegron helps the other drugs work better.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT07278336RecruitingPhase 1
Study of a new drug for advanced ovarian cancer
This trial tests a new drug called ABBV901, given alone or with other anticancer drugs, for people with advanced ovarian, fallopian tube, or primary peritoneal cancer. The goal is to see how well it works and how it affects the body.
Duarte, CaliforniaAges 18 years+ - NCT07261683RecruitingPhase 2
Combination therapy for recurrent ovarian cancer
This trial tests a new combination of chemotherapy, immunotherapy, and a bladder relaxant for ovarian cancer that has come back after initial treatment. It aims to see if adding these drugs together can help control the cancer longer.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06902467Recruiting
Chemotherapy directly into the abdomen after surgery for advanced ovarian cancer
This trial tests giving chemotherapy directly into the abdomen (intraperitoneal) after optimal surgery for advanced ovarian cancer. It aims to see if this approach is safe and effective for women who have already received 3-4 cycles of chemotherapy before surgery.
MurciaAges 18–70 - NCT07225270RecruitingPhase 3
Study of Rina-S plus care for ovarian cancer maintenance
This trial tests whether adding Rina-S to standard maintenance therapy helps prevent cancer from returning in people with recurrent platinum-sensitive ovarian cancer who have responded to second-line platinum-based chemotherapy.
Miami, FloridaAges 18 years+ - NCT07218809RecruitingPhase 3
Comparison of AZD5335 vs standard treatments for advanced ovarian cancer
This trial tests a new drug, AZD5335, against standard treatments (mirvetuximab soravtansine or chemotherapy) for women with platinum-resistant ovarian cancer. It aims to see if AZD5335 works better based on the level of a protein called FRα on your tumor cells.
Birmingham, AlabamaAges 18 years+ - NCT06014528RecruitingPhase 2
IN10018 plus liposomal doxorubicin for platinum-resistant ovarian cancer
This trial tests if adding the drug IN10018 to standard chemotherapy (liposomal doxorubicin) can help women with ovarian cancer that has stopped responding to platinum-based treatments. It aims to see if the combination works better than chemotherapy alone.
BeijingAges 18 years+ - NCT07171528RecruitingPhase 2
Surgery after chemo for recurrent ovarian cancer
This trial is for people with recurrent ovarian cancer whose disease came back more than 6 months after platinum chemo. It tests whether removing the recurrent tumor with surgery (after more chemo) can help—even if surgery wasn't an option before.
Goyang-si, Gyeonggi-doAges 19–80 - NCT07100288Recruiting
Study of the ovary ligament in ovarian cancer patients
This trial looks at a specific ligament near the ovary in patients with epithelial ovarian cancer to better understand the disease. It is for people who had surgery with no cancer left behind.
Las Palmas de Gran CanariaAges 18 years+ - NCT07075939Recruiting
Centralized care for ovarian cancer: a study of outcomes
This study looks at whether having ovarian cancer care coordinated by a special team (Multidisciplinary Tumor Board) leads to better outcomes. It reviews records of patients treated between 2018 and 2023 to understand how centralization affects their health.
Carpi, ModenaAges 18–99 - NCT07069335RecruitingPhase 1
Studying a new form of olaparib for BRCA-mutated ovarian cancer
This study tests a new form of a drug similar to olaparib (Lynparza) in people with BRCA-mutated ovarian cancer. It looks at how the drug works in the body and checks for safety, to see if the new formulation is as effective and safe as the current one.
Seoul, Songpa DistrictAges 19–74 - NCT07067255RecruitingPhase 1/Phase 2
Sequential CAR-T cells for advanced ovarian cancer with CD146 and GPC3
This trial tests a new type of immunotherapy called CAR-T cells that are designed to attack ovarian cancer cells that have two specific markers (CD146 and GPC3). It is for people with advanced ovarian cancer who have already tried standard treatments like platinum-based chemotherapy and need new options.
Beijing, Beijing MunicipalityAges 21–90 - NCT07059845RecruitingPhase 2
Studying mirvetuximab combos for ovarian cancer
This trial tests multiple combinations of the drug mirvetuximab soravtansine with other treatments for people with ovarian cancer. It aims to see how well these combos work and what side effects they cause.
La Jolla, CaliforniaAges 18 years+ - NCT07030907RecruitingPhase 1
Testing OPB-101 for platinum-resistant ovarian cancer
This trial tests a new treatment called OPB-101 for people with a type of ovarian, peritoneal, or fallopian tube cancer that has stopped responding to platinum chemotherapy. The goal is to see if it is safe and if it can help shrink or slow the cancer.
Detroit, MichiganAges 18 years+ - NCT07022535RecruitingPhase 2
Personalized timing of surgery for advanced ovarian cancer
This trial checks if adjusting the timing of surgery (interval debulking surgery) after chemotherapy can improve outcomes for people with advanced ovarian cancer. It's for those who cannot have surgery right away and will receive chemotherapy first.
Hong KongAges 18 years+
Hear when a new Epithelial Ovarian Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for epithelial ovarian cancer?
- Yes. Clin2 currently lists 235 recruiting epithelial ovarian cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a epithelial ovarian cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a epithelial ovarian cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.